Amicogen Inc is a Korea-based company engaged in the development, production and distribution of enzymes, bio new materials and healthcare food. The Companyâ€™s products consist of special enzymes, N-acetylglucosamine (NAG), pinitol, D-Chiro-inositol (DCI), collagen peptides (CP) and protein A chromatography resins. The Company sells its products in domestic and overseas markets.

Employees

236

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
24/06/26	₩1,625.00	-4.07%	933,492
24/06/26	₩1,694.00	-2.08%	1,426,922
23/06/26	₩1,730.00	+17.37%	6,481,010
22/06/26	₩1,474.00	-2.58%	1,978,694
19/06/26	₩1,513.00	+15.41%	6,758,591

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 25/06/2026			5-day change	1st Jan Change
1,625.00 ^KRW	-4.07%		+22.73%	-8.81%

06-21	Amicogen, Inc. announced that it expects to receive KRW 9.999998911 billion in funding	CI
05-14	Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	119B 77.41M 68.15M 62.86M 58.79M 110M 7.3B 112M 755M 293M 3.6B 291M 284M 12.52B	P/E 2024	-4.02x	P/E 2025	-3.28x
Enterprise Value	206B 134M 118M 109M 102M 190M 12.61B 194M 1.31B 506M 6.22B 502M 491M 21.64B	EV / Sales 2024	1.86x	EV / Sales 2025	4.43x
Free-Float	95.13%	Yield 2024 *	-	Yield 2025	-

06-21	Amicogen, Inc. announced that it expects to receive KRW 9.999998911 billion in funding	CI
05-14	Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-23	Amicogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-14	Amicogen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
21/09/25	Amicogen, Inc.(KOSDAQ:A092040) added to S&P Global BMI Index	CI
20/08/25	Bio-Works Launches WorkBeads AffimAb Edge: Strategic Expansion in the Protein A Resin Market	CI
14/08/25	Amicogen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
11/08/25	Amicogen, Inc. announced that it has received KRW 7 billion in funding from BIFIDO Co., Ltd.	CI
14/05/25	Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
24/04/25	Amicogen, Inc.(KOSDAQ:A092040) dropped from S&P Global BMI Index	CI
19/03/25	Amicogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
09/12/24	An undisclosed buyer agreed to acquire an unknown stake in Amicogen Biopharm Co., Ltd. from Amicogen, Inc. for KRW 54.7 billion.	CI
20/11/24	Enzynomics Co., Ltd. completed the acquisition of 37.32% stake in SKINMED Co., Ltd. from Amicogen, Inc..	CI

20/06/24	Bio-Works and Amicogen have concluded their technology transfer project.	AQ
10/09/21	Bio Works Technologies : Amicogen Inc enters into agreement to divest its ownership in Bio-Works	AQ
17/02/21	Bio Works Technologies : Works signs licensing agreement with Amicogen Inc to establish local manufacturing of agarose resins in South Korea	AQ

Amicogen, Inc. Share Price

Stocks

A092040

KR7092040005

Biotechnology & Medical Research

Valuation: Amicogen, Inc.

Chart: Amicogen, Inc.

Latest news : Amicogen, Inc.

Press Releases: Amicogen, Inc.

News in other languages: Amicogen, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Amicogen, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	-4.07%
1 week	+22.73%
Current month	+3.17%
1 month	-10.76%
3 months	+9.80%
6 months	-11.54%
Current year	-8.81%

1 week	1,300	1,890
1 month	1,218	1,890
Current year	1,160	2,300
1 year	1,160	4,440
3 years	1,160	9,790
5 years	1,160	23,500
10 years	1,160	24,825

Manager	Title	Age	Since
Jjeo Pyo CEO	Chief Executive Officer	53	-
Young-Chul Yoon PRN	Corporate Officer/Principal	55	27/03/2024
Chun-Gu Kim AUD	Comptroller/Controller/Auditor	69	26/03/2025

Director	Title	Age	Since
Jun-Ho Kim BRD	Director/Board Member	56	25/02/2025
Jjeo Pyo BRD	Director/Board Member	53	-
Young-Chul Yoon BRD	Director/Board Member	55	27/03/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
03-02	Ji-Seong So	Buy	Director	435	0.0006%
03-02	Young-Chul Yoon	Buy	Director	109	0.0002%
02-26	Eun-seong Hwang	Buy		4,000	0.0072%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AMICOGEN, INC.	-4.07%	+22.73%	-55.42%	-82.56%	77.41M
ARGENX SE	+3.95%	+1.91%	+60.92%	+117.15%	52.88B
WUXI APPTEC CO., LTD.	+8.55%	+17.52%	+72.65%	+82.31%	50.98B
BIONTECH SE	+0.55%	-0.28%	-13.51%	-15.23%	22.81B
INSMED INCORPORATED	+3.27%	+11.81%	+2.16%	+437.97%	22.43B
WUXI BIOLOGICS (CAYMAN) INC.	+2.03%	+10.85%	+30.31%	-12.32%	17.01B
GENMAB A/S	+0.88%	+6.05%	+31.17%	-33.61%	15.91B
EXELIXIS, INC.	+1.07%	+3.10%	+22.95%	+175.03%	13.29B
PHARMAESSENTIA CORPORATION	+3.02%	+18.32%	+141.11%	+308.04%	13.58B
MADRIGAL PHARMACEUTICALS, INC.	+1.92%	+1.43%	+84.77%	+118.09%	11.75B
Average	+2.08%	+5.21%	+37.71%	+109.49%	22.07B
Weighted average by Cap.	+3.83%	+5.27%	+49.34%	+122.38%

	2024	2025
Net sales	174B 113M 99.13M 91.43M 85.52M 160M 10.61B 163M 1.1B 426M 5.24B 423M 414M 18.21B	41.98B 27.23M 23.97M 22.11M 20.68M 38.75M 2.57B 39.47M 266M 103M 1.27B 102M 100M 4.4B
Net income	-52.79B -34.24M -30.14M -27.8M -26M -48.72M -3.23B -49.63M -334M -129M -1.59B -129M -126M -5.54B	-29.96B -19.43M -17.11M -15.78M -14.76M -27.65M -1.83B -28.17M -190M -73.45M -903M -72.95M -71.37M -3.14B
Net Debt	112B 72.33M 63.68M 58.73M 54.93M 103M 6.82B 105M 706M 273M 3.36B 272M 266M 11.7B	86.91B 56.37M 49.62M 45.77M 42.81M 80.21M 5.31B 81.71M 550M 213M 2.62B 212M 207M 9.12B